SIBN Overview

Price Target Increase: Needham analyst David Saxon raised the price target for SI-Bone (SIBN) from $24 to $27 and maintained a Buy rating on the shares.

Conviction List Addition: The stock has been added to Needham's 'Conviction List' and named as the firm's '2026 Top Pick', replacing Alcon (ALC).

Growth Potential: Needham believes SI-Bone can exceed near-term estimates, leading to increased profitability, particularly with upcoming product launches.

Surgeon Adoption: The firm anticipates that these product launches will enhance active surgeon adoption across SI-Bone's portfolio, driving higher utilization.

Analyst Upgrades: Morgan Stanley upgraded Accenture Plc from Equal-Weight to Overweight, raising its price target from $271 to $320, while Cantor Fitzgerald upgraded Microchip Technology Inc from Neutral to Overweight with a target increase from $65 to $85.

Price Target Increases: Wedbush raised Tyra Biosciences Inc's target from $30 to $37, and Chardan Capital increased Palvella Therapeutics Inc's target from $110 to $174, both maintaining positive ratings.

Mixed Ratings: Baird cut Dentsply Sirona Inc's price target from $14 to $12 while maintaining a Neutral rating, contrasting with their upgrade of Tandem Diabetes Care Inc from Neutral to Outperform with a target increase from $18 to $30.

Other Notable Changes: Goldman Sachs upgraded Rockwell Automation Inc from Sell to Neutral, raising its target from $329 to $448, while Needham increased SI-Bone Inc's target from $24 to $27, maintaining a Buy rating.

Company Presentation: SI-BONE, Inc. will present at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, and recently reported a narrowed net loss of $4.6 million for Q3 2025.

Financial Performance: Total revenue for Q3 2025 increased by 19% to $48.7 million, with U.S. revenue rising 18% to $45.4 million, driven by strong demand for their products.

Product Highlights: The iFuse Bedrock Granite and TORQ TNT continue to be the main revenue-generating products for SI-BONE, contributing to the company's growth.

Future Outlook: SI-BONE anticipates fiscal year 2025 revenue between $190 million and $192 million, reflecting a positive growth trajectory compared to $167.2 million in fiscal year 2024.

Financial Performance: SI-BONE Inc. reported a loss of -$4.57 million for the third quarter, an improvement from -$6.58 million in the same period last year.

Earnings Per Share: The company's earnings per share (EPS) were -$0.11, compared to -$0.16 in the previous year.

Revenue Growth: Revenue increased by 20.6% to $48.66 million, up from $40.34 million year-over-year.

Future Guidance: SI-BONE Inc. provided full-year revenue guidance of $198 to $200 million.